-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, despite many advances in the treatment of metastasis non-small cell lung cancer (NSCLC), the overall prognostication of patients is still not optimistic and new treatment options are still needed.
, the New England Journal of Medicine (NEJM) published the results of a global Phase 3 trial of the PD-L1 inhibitor atezolizumab for first-line treatment of advanced NSCLC, which extended the survival of patients with high expression of PD-L1 by 7.1 months compared to standard platinum chemotherapy.
Screenshot Source: New England Journal of Medicine This randomized, open-label Phase 3 clinical trial included 572 metastasis non-scaly or scaly NSCLC patients who had not previously received chemotherapy and had at least 1% of tumor cells or at least 1% of tumor-immersed cells expressing PD-L1.
this includes 18 patients with EGFR mutations or ALK mutations who have received targeted treatment, and 18 patients who have been excluded from the main analysis group but included in the safety analysis, as new data suggest that these patients may have difficulty benefiting from immuno-checkpoint inhibitor monodyme therapy.
all patients were randomly grouped at 1:1 to receive atilijutrobe or chemotherapy.
In the subgroup of 205 patients with the highest expression of PD-L1 and EGFR and ALK wild type, the middle total survival benefit of the athilation group was most significant, with a 41% lower risk of death than the chemotherapy group leader of 7.1 months (20.2 months vs 13.1 months).
two groups had a non-progressed survival period of 8.1 months and 5.0 months, respectively, and a 37% reduction in the risk of disease progressity or death in the atiliju monoantigroup.
In the subgroup of 328 patients with high or moderate expression of PD-L1 and wild type EGFR and ALK, the median total survival of the athilation group and chemotherapy group was 18.2 months and 14.9 months, respectively, and the risk of death of the athilation group was reduced by 28%.
two groups had a non-progressed survival period of 7.2 months and 5.5 months, respectively, and a 33 per cent reduction in the risk of disease progress or death in the atili-juju monoantigroup.
In the 554 subgroups that expressed any PD-L1 and were EGFR and ALK wild, the medium total lifetimes of the atili-pearl monoantigen and chemotherapy groups were 17.5 months and 14.1 months, respectively, but the statistical differences were not significant.
the total survival of the atili-pearl monoantigen and chemotherapy groups in patients with different PD-L1 expression levels.
(Photo Source: Resources) In addition, in patients with higher blood tumor mutation load (TMB), the overall survival and progress-free survival rates of the atili-pearl monoantigen group showed a better trend.
Among all patients who could assess safety, the proportion of adverse events occurred in the atili-pearl monoantitor group was 90.2%, the proportion of adverse events in the chemotherapy group was 94.7%;
team noted that the safety of atilijucin in this study is consistent with previous observations in the study of atilijucin monodrug therapy.
References . . . Roy S. Herbst, et al., (2020). Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med, DOI:10.1056/NEJMoa1917346 Retrieved October 13, 2020, from.